Skip to content
MARKETS / NASDAQ / LEXX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Lexaria Bioscience Corp. LEXX

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$705,923
▲ 52.0% YoY
$-11.9M
$-10.5M
In brief

What this company does

DehydraTECH can be implemented in a multitude of ingestible product formats including oral suspensions, tablets, capsules, foods, beverages, and oral pouches. DehydraTECH is a technology incorporated into the formulation and manufacturing process of new or existing orally ingestible products. A part of our business plan is to encourage new and existing industry participants to license and utilize DehydraTECH to enable enhanced performance of their developmental and commercial stage products. Poviva is now the wholly-owned subsidiary of Lexaria and the named owner on all of the patents filed in connection with DehydraTECH.

Written from the business description in Lexaria Bioscience Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 28 November 2025. Every sentence was checked against that document before publication.

Growth
USD 705,923.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.7 · Net income -11.9
-4M-8M201020122014201620182020202220242025
Compound annual growth
+40.3%
+17.5%
+47.3%
+4.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−1687 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -1683.0% · Net -1687.4%
-5000%-10000%201020122014201620182020202220242025
ROE
FY2025 · ROE -215.9%
-100%-200%201020122014201620182020202220242025

Each USD of equity lost 216 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -10.5
-4M-8M201020122014201620182020202220242025

Total assetsUSD 4.2M
EquityUSD 3.0M
CashUSD 1.8M
Current ratio2.32×

Equity funds 72% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0····−0.0−0.0−0.0····
EBITDA $B−0.0−0.0··−0.0····−0.0−0.0·····
Income tax $B···0.00.00.00.00.00.00.0······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0··−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0·−0.0−0.0·−0.0−0.0−0.0·0.0−0.0−0.0−0.0
EPS, diluted $−0.66−0.47−1.01·−0.95−1.47−0.05−0.09−0.03−0.03−0.04−0.14−0.02−0.02−0.04−0.04
Dividend / sh $················
Payout %················
ROE %−215.9−104.6−121.3−68.5−51.1−164.3−170.5−256.4−127.2−246.0−159.3−81.7··−22.4−25.7
Shares out B0.020.020.010.010.010.000.080.080.070.050.040.030.020.020.020.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 76 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 19 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsAugust 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image